In this study, 571 patients with HCV-HCC were randomised to receive sintilimab (a PD-1 inhibitor) plus IBI305 (a bevacizumab biosimilar) or sorafenib in the first-line setting. Here, PDCD1 is linked to hepatocellular carcinoma.